These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 15765011)

  • 1. [Diagnostic utility of procalcitonin in community-acquired respiratory tract infections--a literature review].
    Wróblewski T; Marcisz C; Kurzawska G
    Postepy Hig Med Dosw (Online); 2004; 58():495-505. PubMed ID: 15765011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators.
    Christ-Crain M; Müller B
    Eur Respir J; 2007 Sep; 30(3):556-73. PubMed ID: 17766633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Usefulness of serum procalcitonin measurement in the diagnosis of respiratory infectious diseases].
    Kurata K; Kazuyori T; Shimizu K; Kubota M; Hamaguchi R; Wakaki M; Goto T; Onaka A; Kato R; Oyamada Y
    Nihon Kokyuki Gakkai Zasshi; 2010 Sep; 48(9):654-60. PubMed ID: 20954366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum procalcitonin and respiratory tract infections].
    Zarka V; Valat C; Lemarié E; Boissinot E; Carré P; Besnard JC; Diot P
    Rev Pneumol Clin; 1999 Dec; 55(6):365-9. PubMed ID: 10685471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procalcitonin as a biomarker in respiratory tract infection.
    Gilbert DN
    Clin Infect Dis; 2011 May; 52 Suppl 4():S346-50. PubMed ID: 21460294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia.
    Müller B; Harbarth S; Stolz D; Bingisser R; Mueller C; Leuppi J; Nusbaumer C; Tamm M; Christ-Crain M
    BMC Infect Dis; 2007 Mar; 7():10. PubMed ID: 17335562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Procalcitonin as a biomarker in infections].
    Christ-Crain M
    Praxis (Bern 1994); 2007 Jun; 96(25-26):1017-21. PubMed ID: 17639964
    [No Abstract]   [Full Text] [Related]  

  • 8. Biological markers to determine eligibility in trials for community-acquired pneumonia: a focus on procalcitonin.
    Niederman MS
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S127-32. PubMed ID: 18986278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers and community-acquired pneumonia: tailoring management with biological data.
    Torres A; Ramirez P; Montull B; Menéndez R
    Semin Respir Crit Care Med; 2012 Jun; 33(3):266-71. PubMed ID: 22718212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of procalcitonin in adult patients with community-acquired pneumonia--a systematic review.
    Berg P; Lindhardt BØ
    Dan Med J; 2012 Mar; 59(3):A4357. PubMed ID: 22381083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of procalcitonin in managing adult patients with respiratory tract infections.
    Schuetz P; Amin DN; Greenwald JL
    Chest; 2012 Apr; 141(4):1063-1073. PubMed ID: 22474148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-operative kinetics of procalcitonin after lung transplantation.
    Desmard M; Benbara A; Boudinet S; Mal H; Dehoux M; Thabut G; Montravers P
    J Heart Lung Transplant; 2015 Feb; 34(2):189-94. PubMed ID: 25447581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of serum procalcitonin levels in pulmonary tuberculosis.
    Ugajin M; Miwa S; Shirai M; Ohba H; Eifuku T; Nakamura H; Suda T; Hayakawa H; Chida K
    Eur Respir J; 2011 Feb; 37(2):371-5. PubMed ID: 20530033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic value of procalcitonin in community-acquired pneumonia.
    Horie M; Ugajin M; Suzuki M; Noguchi S; Tanaka W; Yoshihara H; Kawakami M; Kichikawa Y; Sakamoto Y
    Am J Med Sci; 2012 Jan; 343(1):30-5. PubMed ID: 22207498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of serum procalcitonin in evaluating severity of community-acquired pneumonia in childhood.
    Don M; Valent F; Korppi M; Falleti E; De Candia A; Fasoli L; Tenore A; Canciani M
    Scand J Infect Dis; 2007; 39(2):129-37. PubMed ID: 17366029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Procalcitonin, a new marker for bacterial infections].
    Ferrière F
    Ann Biol Clin (Paris); 2000; 58(1):49-59. PubMed ID: 10673614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in community-acquired pneumonia.
    Krüger S; Welte T
    Expert Rev Respir Med; 2012 Apr; 6(2):203-14. PubMed ID: 22455492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of procalcitonin concentration in clinical diagnosis].
    Czerwionka-Szaflarska M; Parzecka M
    Pol Merkur Lekarski; 2005 Oct; 19(112):584-6. PubMed ID: 16379332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin.
    Sitter T; Schmidt M; Schneider S; Schiffl H
    J Nephrol; 2002; 15(3):297-301. PubMed ID: 12113602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial quantification of procalcitonin (PCT) predicts clinical outcome and prognosis in patients with community-acquired pneumonia (CAP).
    Tamura M; Watanabe M; Nakajima A; Kurai D; Ishii H; Takata S; Nakamoto K; Sohara E; Honda K; Nakamura M; Inui T; Wada H; Takizawa H; Goto H
    J Infect Chemother; 2014 Feb; 20(2):97-103. PubMed ID: 24462441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.